Hybrigenics

Created in 1997, Hybrigenics is a bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative diseases.Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist being studied in three potential indications :

  • alone in chronic lymphocytic leukaemia
  • in combination with imatinib in chronic myeloid leukaemia
  • in prostate cancer, for use with current standards of care

Hybrigenics’ research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications.

Source: Cofisem

Address

Hybrigenics

3-5 impasse Reille

FR-75014 Paris

France

Phone Number : +33 (0)1 58 10 38 00

Fax : +33 (0)1 58 10 38 49

http://www.hybrigenics.com

Codes and Classification

IPO Date : December 17th 2007

Type : Stock – Ordinary Stock

ISIN : FR0004153930

Market Type : ALTERNEXT PARIS

Mnemo : ALHYG

Company Profile
Financial Information
Stock Exchange Prices
© Copyright Allegra Finance - Financing company, introduction stock exchange alternext, listing sponsor